Biotechnology
Cancer Prevention
Biopharmaceutical

Sorrento Therapeutics

$2.58
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.08 (3.20%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell SRNE and other stocks, options, ETFs, and crypto commission-free!

About SRNE

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. Read More The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.

Employees
382
Headquarters
San Diego, California
Founded
2006
Market Cap
305.78M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.09M
High Today
$2.58
Low Today
$2.50
Open Price
$2.50
Volume
600.31K
52 Week High
$6.88
52 Week Low
$1.80

Collections

Biotechnology
Cancer Prevention
Biopharmaceutical
Therapy
Research And Development
Health
Pharmaceutical
Manufacturing

SRNE News

Seeking AlphaJun 20

Stacking The Deck: Henry Ji Is Setting The Stage For A Sorrento Therapeutics Breakout

4,101
BenzingaJun 19

Sorrento Therapeutics Shares Move On RTX Trial Update

1,820

SRNE Earnings

-$0.73
-$0.43
-$0.12
$0.18
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.34 per share
Actual
Expected Aug 9, After Hours

Popular Stocks

More SRNE News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.